Martin Fassnacht

List of Publications by Citations

166 papers	12,394 citations	56 h-index	110 g-index
181 ext. papers	15,165 ext. citations	7.5 avg, IF	6.06 L-index

#	Paper	IF	Citations
166	Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. *European Journal of Endocrinology*, **2016**, 175, G1-G34	6.5	715
165	Adjuvant mitotane treatment for adrenocortical carcinoma. *New England Journal of Medicine*, **2007**, 356, 2372-80	59.2	568
164	Clinical review: Adrenocortical carcinoma: clinical update. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 2027-37	5.6	561
163	Combination chemotherapy in advanced adrenocortical carcinoma. *New England Journal of Medicine*, **2012**, 366, 2189-97	59.2	510
162	Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. *Cancer*, **2009**, 115, 243-50	6.4	446
161	Integrated genomic characterization of adrenocortical carcinoma. *Nature Genetics*, **2014**, 46, 607-12	36.3	423
160	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. *Cancer Cell*, **2017**, 31, 181-193	24.3	350
159	Mutations in the deubiquitinase gene USP8 cause Cushing's disease. *Nature Genetics*, **2015**, 47, 31-8	36.3	339
158	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. *Cancer Cell*, **2016**, 29, 723-736	24.3	324
157	European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. *European Journal of Endocrinology*, **2018**, 179, G1-G46	6.5	303
156	Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 3775-84	5.6	293
155	Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome. *New England Journal of Medicine*, **2014**, 370, 1019-28	59.2	284
154	Update in adrenocortical carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 4551-64	5.6	280
153	Adrenocortical carcinoma: a clinician's update. *Nature Reviews Endocrinology*, **2011**, 7, 323-35	15.2	265
152	High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 407-16	5.6	210
151	Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. *Lancet Oncology, The*, **2015**, 16, 426-35	21.7	209
150	Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. *European Journal of Endocrinology*, **2010**, 162, 597-602	6.5	209

149	Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. *European Urology*, **2010**, 58, 609-15	10.2	207
148	Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 3912-22	5.6	201
147	Clinical management of adrenocortical carcinoma. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2009**, 23, 273-89	6.5	200
146	Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 841-9	5.6	199
145	Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 4501-4	5.6	181
144	Management of adrenocortical carcinoma. *Clinical Endocrinology*, **2004**, 60, 273-87	3.4	160
143	High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, E161-71	5.6	156
142	Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. *European Journal of Endocrinology*, **2009**, 161, 355-61	6.5	132
141	Radiotherapy in adrenocortical carcinoma. *Cancer*, **2009**, 115, 2816-23	6.4	128
140	Plasma concentrations of o,pÐDD, o,pÐDA, and o,pÐDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 1844-51	5.6	125
139	Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 2057-62	5.6	122
138	Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 4925-32	5.6	118
137	Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. *Annals of Surgery*, **2012**, 255, 363-9	7.8	118
136	Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells. *Endocrinology*, **2015**, 156, 3895-908	4.8	115
135	Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 3495-503	5.6	115
134	The role of surgery in the management of recurrent adrenocortical carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 181-91	5.6	110
133	-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. *Clinical Cancer Research*, **2011**, 17, 328-36	12.9	110
132	MANAGEMENT OF ENDOCRINE DISEASE: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis. *European Journal of Endocrinology*, **2016**, 175, R51-64	6.5	106

131	Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5-reductase, explaining the need for personalized glucocorticoid and androgen replacement. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 161-71	5.6	104
130	Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. *European Journal of Endocrinology*, **2010**, 162, 349-56	6.5	97
129	New targets and therapeutic approaches for endocrine malignancies. *Pharmacology & Therapeutics*, **2009**, 123, 117-41	13.9	90
128	Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. *European Urology*, **2014**, 65, 832-8	10.2	87
127	Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. *Clinical Endocrinology*, **2011**, 75, 585-91	3.4	87
126	Mitotane for adrenocortical carcinoma treatment. *Current Opinion in Investigational Drugs*, **2005**, 6, 386-94		87
125	FATE1 antagonizes calcium- and drug-induced apoptosis by uncoupling ER and mitochondria. *EMBO Reports*, **2016**, 17, 1264-80	6.5	86
124	Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. *Journal of Clinical Oncology*, **2010**, 28, e401-2; author reply e403	2.2	84
123	TP53 germline mutations in adult patients with adrenocortical carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, E476-85	5.6	80
122	Contemporary management of adrenocortical carcinoma. *European Urology*, **2011**, 60, 1055-65	10.2	77
121	Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 1358-1365	5.6	75
120	[123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 2358-65	5.6	72
119	Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated -Methylated Catecholamine Metabolites. *Clinical Chemistry*, **2018**, 64, 1646-1656	5.5	67
118	Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal Cushing's syndrome: a European multicentric study. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E2093-100	5.6	67
117	Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 1686-1695	5.6	66
116	Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. *Endocrine-Related Cancer*, **2009**, 16, 919-28	5.7	64
115	DIAGNOSIS OF ENDOCRINE DISEASE: The diagnostic performance of adrenal biopsy: a systematic review and meta-analysis. *European Journal of Endocrinology*, **2016**, 175, R65-80	6.5	60
114	Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. *European Journal of Endocrinology*, **2016**, 174, 363-72	6.5	59

113	CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 312-318	5.6	59
112	[131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 914-22	5.6	56
111	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 773-781	18.1	56
110	Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 4511-4523	5.6	55
109	Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer. *Clinical Cancer Research*, **2012**, 18, 3452-61	12.9	54
108	Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 4323-4332	5.6	50
107	Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 22269-22274	11.5	49
106	PKA catalytic subunit mutations in adrenocortical Cushingâ adenoma impair association with the regulatory subunit. *Nature Communications*, **2014**, 5, 5680	17.4	49
105	Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. *Endocrine-Related Cancer*, **2009**, 16, 907-18	5.7	48
104	Single nucleotide polymorphism array profiling of adrenocortical tumors--evidence for an adenoma carcinoma sequence?. *PLoS ONE*, **2013**, 8, e73959	3.7	47
103	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. *Hypertension*, **2018**, 71, 317-325	8.5	46
102	Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 3526-38	5.6	46
101	Side population does not define stem cell-like cancer cells in the adrenocortical carcinoma cell line NCI h295R. *Endocrinology*, **2008**, 149, 1314-22	4.8	44
100	Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. *Modern Pathology*, **2010**, 23, 1596-604	9.8	43
99	Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomas. *Journal of Clinical Investigation*, **2016**, 126, 3383-8	15.9	40
98	Frequency and clinical correlates of somatic Ying Yang 1 mutations in sporadic insulinomas. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, E776-82	5.6	39
97	What is the best approach to an apparently nonmetastatic adrenocortical carcinoma?. *Clinical Endocrinology*, **2010**, 73, 561-5	3.4	36
96	Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients. *Clinical Nuclear Medicine*, **2017**, 42, e29-e34	1.7	35

95	Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry. *European Journal of Endocrinology*, **2015**, 172, 415-22	6.5	35
94	Functional characterization of adrenal lesions using [123I]IMTO-SPECT/CT. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 1508-18	5.6	35
93	Metastatic adrenocortical carcinoma: results of 56 pulmonary metastasectomies in 24 patients. *Annals of Thoracic Surgery*, **2011**, 92, 1965-70	2.7	35
92	DNA Methylation Is an Independent Prognostic Marker of Survival in Adrenocortical Cancer. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 923-932	5.6	35
91	Deficits in the management of patients with adrenocortical carcinoma in Germany. *Deutsches Ärzteblatt International*, **2010**, 107, 885-91	2.5	34
90	Clinical impact of TP53 alterations in adrenocortical carcinomas. *Langenbeckis Archives of Surgery*, **2012**, 397, 209-16	3.4	33
89	CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma. *PLoS ONE*, **2014**, 9, e105855	3.7	33
88	[□□□]Iodometomidate imaging in adrenocortical carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 2755-64	5.6	33
87	Low SGK1 expression in human adrenocortical tumors is associated with ACTH-independent glucocorticoid secretion and poor prognosis. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, E2251-60	5.6	33
86	Decoding the genetic basis of Cushing□ disease: USP8 in the spotlight. *European Journal of Endocrinology*, **2015**, 173, M73-83	6.5	32
85	Driver mutations in USP8 wild-type Cushing□ disease. *Neuro-Oncology*, **2019**, 21, 1273-1283	1	32
84	EJE prize 2014: current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go?. *European Journal of Endocrinology*, **2014**, 171, R1-R11	6.5	32
83	Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. *JAMA Oncology*, **2019**, 5, 1440-1447	13.4	31
82	Single nucleotide polymorphism microarray analysis in cortisol-secreting adrenocortical adenomas identifies new candidate genes and pathways. *Neoplasia*, **2012**, 14, 206-18	6.4	28
81	Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	27
80	Next-generation therapies for adrenocortical carcinoma. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2020**, 34, 101434	6.5	26
79	Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. *Clinical Endocrinology*, **2010**, 72, 305-11	3.4	26
78	Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma **2020**, 8,		25

77	Dosage-dependent regulation of expression by steroidogenic factor-1 drives adrenocortical carcinoma cell invasion. *Science Signaling*, **2017**, 10,	8.8	24
76	Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome. *Endocrine-Related Cancer*, **2015**, 22, 531-43	5.7	24
75	Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 3491-3498	5.6	24
74	The New Molecular Landscape of Cushing Disease. *Trends in Endocrinology and Metabolism*, **2015**, 26, 573-583	8.8	23
73	High-Resolution Tissue Mass Spectrometry Imaging Reveals a Refined Functional Anatomy of the Human Adult Adrenal Gland. *Endocrinology*, **2018**, 159, 1511-1524	4.8	23
72	Advanced Adrenocortical Carcinoma - What to do when First-Line Therapy Fails?. *Experimental and Clinical Endocrinology and Diabetes*, **2019**, 127, 109-116	2.3	22
71	Sunitinib Inhibits Cell Proliferation and Alters Steroidogenesis by Down-Regulation of HSD3B2 in Adrenocortical Carcinoma Cells. *Frontiers in Endocrinology*, **2011**, 2, 27	5.7	21
70	Expression of LIN28 and its regulatory microRNAs in adult adrenocortical cancer. *Clinical Endocrinology*, **2015**, 82, 481-8	3.4	20
69	Outcome after resection of Adrenocortical Carcinoma liver metastases: a retrospective study. *BMC Cancer*, **2017**, 17, 522	4.8	20
68	Livin/BIRC7 expression as malignancy marker in adrenocortical tumors. *Oncotarget*, **2017**, 8, 9323-9338	3.3	20
67	Impact of USP8 Gene Mutations on Protein Deregulation in Cushing Disease. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 2535-2546	5.6	19
66	A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. *Investigational New Drugs*, **2020**, 38, 1421-1429	4.3	19
65	Topoisomerase 2 and thymidylate synthase expression in adrenocortical cancer. *Endocrine-Related Cancer*, **2017**, 24, 319-327	5.7	18
64	Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	17
63	Alterations in Protein Kinase A Substrate Specificity as a Potential Cause of Cushing Syndrome. *Endocrinology*, **2019**, 160, 447-459	4.8	16
62	Differential expression of the protein kinase A subunits in normal adrenal glands and adrenocortical adenomas. *Scientific Reports*, **2017**, 7, 49	4.9	15
61	Surviving ectopic Cushing syndrome: quality of life, cardiovascular and metabolic outcomes in comparison to Cushing disease during long-term follow-up. *European Journal of Endocrinology*, **2018**, 179, 109-116	6.5	15
60	The New Genetic Landscape of Cushing Disease: Deubiquitinases in the Spotlight. *Cancers*, **2019**, 11,	6.6	15

59	Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. *Cancers*, **2020**, 12,	6.6	14
58	Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. *European Journal of Endocrinology*, **2016**, 174, 343-53	6.5	14
57	Cortisol-related metabolic alterations assessed by mass spectrometry assay in patients with Cushing's syndrome. *European Journal of Endocrinology*, **2017**, 177, 227-237	6.5	13
56	Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma. *Endocrine-Related Cancer*, **2016**, 23, 825-37	5.7	13
55	Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide. *Hormones and Cancer*, **2016**, 7, 211-8	5	13
54	Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	12
53	RNA Sequencing and Somatic Mutation Status of Adrenocortical Tumors: Novel Pathogenetic Insights. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	12
52	Patterns of Lymph Node Recurrence in Adrenocortical Carcinoma: Possible Implications for Primary Surgical Treatment. *Annals of Surgical Oncology*, **2019**, 26, 531-538	3.1	12
51	Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction. *Cell Death and Disease*, **2020**, 11, 192	9.8	11
50	Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells. *Hormones and Cancer*, **2016**, 7, 345-355	5	11
49	Pregnancy in Women Previously Treated for an Adrenocortical Carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 4604-11	5.6	11
48	Osteopontin stimulates invasion of NCI-h295 cells but is not associated with survival in adrenocortical carcinoma. *Journal of Pathology*, **2009**, 218, 232-40	9.4	11
47	Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma. *Frontiers in Endocrinology*, **2020**, 11, 219	5.7	10
46	ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas. *European Journal of Endocrinology*, **2018**, 178, 181-188	6.5	10
45	Prognostic Relevance of Steroid Sulfation in Adrenocortical Carcinoma Revealed by Molecular Phenotyping Using High-Resolution Mass Spectrometry Imaging. *Clinical Chemistry*, **2019**, 65, 1276-1286	5.5	8
44	Cancer-testis Antigen FATE1 Expression in Adrenocortical Tumors Is Associated with A Pervasive Autoimmune Response and Is A Marker of Malignancy in Adult, but Not Children, ACC. *Cancers*, **2020**, 12,	6.6	8
43	Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry. *Experimental and Clinical Endocrinology and Diabetes*, **2019**, 127, 578-584	2.3	8
42	A method for the minimally invasive drug monitoring of mitotane by means of volumetric absorptive microsampling for a home-based therapeutic drug monitoring. *Analytical and Bioanalytical Chemistry*, **2019**, 411, 3951-3962	4.4	7

41	Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma. *Frontiers in Endocrinology*, **2020**, 11, 597878	5.7	7
40	Adrenocortical incidentalomas and bone: from molecular insights to clinical perspectives. *Endocrine* , **2018**, 62, 506-516	4	7
39	Less common genotype variants of TP53 polymorphisms are associated with poor outcome in adult patients with adrenocortical carcinoma. *European Journal of Endocrinology*, **2014**, 170, 707-17	6.5	7
38	Lack of Ubiquitin Specific Protease 8 (USP8) Mutations in Canine Corticotroph Pituitary Adenomas. *PLoS ONE*, **2016**, 11, e0169009	3.7	7
37	Data set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. *Human Pathology*, **2021**, 110, 50-61	3.7	7
36	Intratumor heterogeneity of prognostic DNA-based molecular markers in adrenocortical carcinoma. *Endocrine Connections*, **2020**, 9, 705-714	3.5	6
35	Role of Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) and Its Receptors in Adrenocortical Tumors. *Hormones and Cancer*, **2015**, 6, 225-36	5	5
34	Early Postoperative Circulating miR-483-5p Is a Prognosis Marker for Adrenocortical Cancer. *Cancers*, **2020**, 12,	6.6	5
33	Reply to Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma. *Cancer*, **2009**, 115, 5848-5848	6.4	5
32	What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. *Journal of Personalized Medicine*, **2021**, 11,	3.6	5
31	Inhibition of Cholesterol Esterification in the Adrenal Gland by ATR101/PD132301-2, A Promising Case of Drug Repurposing. *Endocrinology*, **2016**, 157, 1719-21	4.8	5
30	Heat Shock Protein 90 as a Prognostic Marker and Therapeutic Target for Adrenocortical Carcinoma. *Frontiers in Endocrinology*, **2019**, 10, 487	5.7	4
29	S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. *European Journal of Endocrinology*, **2021**, 186, 25-36	6.5	4
28	Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using (18)F-FDG positron emission tomography. *Endocrine*, **2016**, 53, 791-800	4	4
27	A case report of a solitary pancreatic metastasis of an adrenocortical carcinoma. *BMC Surgery*, **2015**, 15, 93	2.3	3
26	Adrenal wash-out CT: moderate diagnostic value in distinguishing benign from malignant adrenal masses. *European Journal of Endocrinology*, **2021**, 186, 183-193	6.5	3
25	Confirmatory testing of primary aldosteronism with saline infusion test and LC-MS/MS. *European Journal of Endocrinology*, **2021**, 184, 167-178	6.5	3
24	Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors : A Cross-Sectional Multicenter Study.. *Annals of Internal Medicine*, **2022**,	8	2

23	Method-Specific Cortisol and Dexamethasone Thresholds Increase Clinical Specificity of the Dexamethasone Suppression Test for Cushing Syndrome. *Clinical Chemistry*, **2021**, 67, 998-1007	5.5	2
22	Identifying New Potential Biomarkers in Adrenocortical Tumors Based on mRNA Expression Data Using Machine Learning. *Cancers*, **2021**, 13,	6.6	2
21	Medikamentöse Therapie des Nebennierenkarzinoms. *Onkologe*, **2018**, 24, 118-123	0.1	1
20	The role of molecular profiling in adrenocortical carcinoma. *Clinical Endocrinology*, **2021**,	3.4	1
19	Expression of the Chemokine Receptor CCR7 in the Normal Adrenal Gland and Adrenal Tumors and Its Correlation with Clinical Outcome in Adrenocortical Carcinoma. *Cancers*, **2021**, 13,	6.6	1
18	Adrenocortical Carcinoma **2010**, 1951-1958		1
17	Epidemiology of Adrenocortical Carcinoma **2009**, 23-29		1
16	Epithelial and Mesenchymal Markers in Adrenocortical Tissues: How Mesenchymal Are Adrenocortical Tissues?. *Cancers*, **2021**, 13,	6.6	1
15	Predicitve Value of FDG Uptake in the Remaining Adrenal Gland Following Adrenalectomy for Adrenocortical Cancer. *Hormone and Metabolic Research*, **2021**, 53, 24-31	3.1	1
14	PKA C□subunit mutation triggers caspase-dependent RII□subunit degradation via Ser phosphorylation. *Science Advances*, **2021**, 7,	14.3	1
13	Novel CYP11B-ligand [I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 1	8.8	1
12	Case Report: Consecutive Adrenal Cushing Syndrome and Cushing Disease in a Patient With Somatic , , and Mutations. *Frontiers in Endocrinology*, **2021**, 12, 731579	5.7	1
11	Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study. *British Journal of Cancer*, **2021**, 125, 1233-1238	8.7	1
10	Management of Patients With Glucocorticoid-Related Diseases and COVID-19. *Frontiers in Endocrinology*, **2021**, 12, 705214	5.7	1
9	Adrenal Functional Imaging.. *Presse Medicale*, **2022**, 51, 104114	2.2	0
8	Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications.. *Frontiers in Endocrinology*, **2021**, 12, 795116	5.7	0
7	Adrenocortical Carcinoma **2016**, 1862-1870.e3		
6	Nebennierenkarzinom. *Springer Reference Medizin*, **2020**, 1-6	0	

List of Publications

5 Laparoskopische Adrenalektomie **2017**, 187-195

4 Clinical Presentation and Initial Diagnosis **2009**, 31-47

3 Nebennierenrindenkarzinom **2010**, 225-230

2 Nebennierenkarzinom **2014**, 1-3

1 Simulation-Based Interpretation of Therapeutically Monitored Cabozantinib Plasma Concentration in Advanced Adrenocortical Carcinoma with Hemodialysis. *Therapeutic Drug Monitoring*, **2021**, 43, 706-711[3,2]